Sponsors (35)
The bill authorizes substantial near-term and tribal-targeted funding and builds flexibility to sustain diabetes programs, but it raises federal spending and depends on future appropriations while creating modest administrative burdens.
People with type 1 diabetes will receive dedicated federal authorization of $160 million per year for 2026 and 2027 to support research, care, and prevention programs.
American Indian and Alaska Native communities will receive targeted authorization of $160 million per year (2026 and 2027) for diabetes programs focused on tribal populations.
Funding is made more stable and flexible (funds available until expended) and a short $40 million bridge for Oct–Dec 2027 is authorized, reducing the risk of short-term service interruptions.
The authorization increases federal outlays and will be paid for by taxpayers, adding to the deficit unless offset elsewhere.
The authorization does not guarantee appropriations—if Congress does not fund the programs as authorized, promised support for patients and tribal programs may not materialize.
Implementing the new provisions adds modest administrative and grant-accounting complexity that agencies and providers will need to manage.
Based on analysis of 2 sections of legislative text.
Adds authorized funding: $160M for FY2026, $160M for FY2027, and $40M for Oct–Dec 2027 for each Special Diabetes Program (available until expended).
Official title: Reauthorize the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians.
Introduced July 8, 2025 by Susan Margaret Collins · Last progress July 8, 2025
Provides new authorized funding for the two Special Diabetes Programs — the Special Diabetes Program for Type I Diabetes and the Special Diabetes Program for Indians — by adding specified dollar amounts for fiscal years 2026 and 2027 and a short fourth-quarter 2027 allocation. The funding amounts are authorized as available until expended and the statutory text is adjusted to insert the new authorizations into the existing funding tables. The provision is narrowly focused: it does not create new programs or policy changes, but extends and specifies funding authorizations for diabetes research and diabetes-related services for American Indian and Alaska Native communities.